Literature DB >> 23677581

Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR.

Noa Stanietsky1, Tihana Lenac Rovis, Ariella Glasner, Einat Seidel, Pinchas Tsukerman, Rachel Yamin, Jonatan Enk, Stipan Jonjic, Ofer Mandelboim.   

Abstract

The activity of natural killer (NK) cells is controlled by a balance of signals derived from inhibitory and activating receptors. TIGIT is a novel inhibitory receptor, recently shown in humans to interact with two ligands: PVR and Nectin2 and to inhibit human NK-cell cytotoxicity. Whether mouse TIGIT (mTIGIT) inhibits mouse NK-cell cytotoxicity is unknown. Here we show that mTIGIT is expressed by mouse NK cells and interacts with mouse PVR. Using mouse and human Ig fusion proteins we show that while the human TIGIT (hTIGIT) cross-reacts with mouse PVR (mPVR), the binding of mTIGIT is restricted to mPVR. We further demonstrate using surface plasmon resonance (SPR) and staining with Ig fusion proteins that mTIGIT binds to mPVR with higher affinity than the co-stimulatory PVR-binding receptor mouse DNAM1 (mDNAM1). Functionally, we show that triggering of mTIGIT leads to the inhibition of NK-cell cytotoxicity, that IFN-γ secretion is enhanced when mTIGIT is blocked and that the TIGIT-mediated inhibition is dominant over the signals delivered by the PVR-binding co-stimulatory receptors. Additionally, we identify the inhibitory motif responsible for mTIGIT inhibition. In conclusion, we show that TIGIT is a powerful inhibitory receptor for mouse NK cells.
© 2013 The Authors. European Journal of Immunology published by Wiley-VCH Verlag GmbH & Co. KGaA Weinheim.

Entities:  

Keywords:  NK cells; PVR; TIGIT

Mesh:

Substances:

Year:  2013        PMID: 23677581      PMCID: PMC3863769          DOI: 10.1002/eji.201243072

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  41 in total

Review 1.  Paired inhibitory and triggering NK cell receptors for HLA class I molecules.

Authors:  M López-Botet; T Bellón; M Llano; F Navarro; P García; M de Miguel
Journal:  Hum Immunol       Date:  2000-01       Impact factor: 2.850

2.  Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155).

Authors:  Anja Fuchs; Marina Cella; Emanuele Giurisato; Andrey S Shaw; Marco Colonna
Journal:  J Immunol       Date:  2004-04-01       Impact factor: 5.422

3.  Generation of a stable cell line producing high-titer self-inactivating lentiviral vectors.

Authors:  K Xu; H Ma; T J McCown; I M Verma; T Kafri
Journal:  Mol Ther       Date:  2001-01       Impact factor: 11.454

4.  Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector.

Authors:  U Blömer; L Naldini; T Kafri; D Trono; I M Verma; F H Gage
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

5.  CD66a interactions between human melanoma and NK cells: a novel class I MHC-independent inhibitory mechanism of cytotoxicity.

Authors:  Gal Markel; Niva Lieberman; Gil Katz; Tal I Arnon; Michal Lotem; Olga Drize; Richard S Blumberg; Erez Bar-Haim; Reuven Mader; Lea Eisenbach; Ofer Mandelboim
Journal:  J Immunol       Date:  2002-03-15       Impact factor: 5.422

Review 6.  Siglecs, sialic acids and innate immunity.

Authors:  P R Crocker; A Varki
Journal:  Trends Immunol       Date:  2001-06       Impact factor: 16.687

7.  Kinetics of interaction of HLA-C ligands with natural killer cell inhibitory receptors.

Authors:  M Valés-Gómez; H T Reyburn; M Mandelboim; J L Strominger
Journal:  Immunity       Date:  1998-09       Impact factor: 31.745

8.  Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112).

Authors:  Satoko Tahara-Hanaoka; Kazuko Shibuya; Yuko Onoda; Hua Zhang; Satoshi Yamazaki; Akitomo Miyamoto; Shin-Ichiro Honda; Lewis L Lanier; Akira Shibuya
Journal:  Int Immunol       Date:  2004-04       Impact factor: 4.823

9.  Protection from lysis by natural killer cells of group 1 and 2 specificity is mediated by residue 80 in human histocompatibility leukocyte antigen C alleles and also occurs with empty major histocompatibility complex molecules.

Authors:  O Mandelboim; H T Reyburn; M Valés-Gómez; L Pazmany; M Colonna; G Borsellino; J L Strominger
Journal:  J Exp Med       Date:  1996-09-01       Impact factor: 14.307

10.  Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule.

Authors:  Cristina Bottino; Roberta Castriconi; Daniela Pende; Paola Rivera; Marina Nanni; Barbara Carnemolla; Claudia Cantoni; Jessica Grassi; Stefania Marcenaro; Nicolas Reymond; Massimo Vitale; Lorenzo Moretta; Marc Lopez; Alessandro Moretta
Journal:  J Exp Med       Date:  2003-08-11       Impact factor: 14.307

View more
  81 in total

1.  IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.

Authors:  Joe-Marc Chauvin; Mignane Ka; Ornella Pagliano; Carmine Menna; Quanquan Ding; Richelle DeBlasio; Cindy Sanders; Jiajie Hou; Xian-Yang Li; Soldano Ferrone; Diwakar Davar; John M Kirkwood; Robert J Johnston; Alan J Korman; Mark J Smyth; Hassane M Zarour
Journal:  Clin Cancer Res       Date:  2020-06-26       Impact factor: 12.531

2.  The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions.

Authors:  Christopher J Chan; Ludovic Martinet; Susan Gilfillan; Fernando Souza-Fonseca-Guimaraes; Melvyn T Chow; Liam Town; David S Ritchie; Marco Colonna; Daniel M Andrews; Mark J Smyth
Journal:  Nat Immunol       Date:  2014-03-23       Impact factor: 25.606

3.  Recognition of nectin-2 by the natural killer cell receptor T cell immunoglobulin and ITIM domain (TIGIT).

Authors:  Felix A Deuss; Benjamin S Gully; Jamie Rossjohn; Richard Berry
Journal:  J Biol Chem       Date:  2017-05-17       Impact factor: 5.157

Review 4.  Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer.

Authors:  Nicholas Borcherding; Ryan Kolb; Jodi Gullicksrud; Praveen Vikas; Yuwen Zhu; Weizhou Zhang
Journal:  J Mol Biol       Date:  2018-05-22       Impact factor: 5.469

Review 5.  Recognition of tumors by the innate immune system and natural killer cells.

Authors:  Assaf Marcus; Benjamin G Gowen; Thornton W Thompson; Alexandre Iannello; Michele Ardolino; Weiwen Deng; Lin Wang; Nataliya Shifrin; David H Raulet
Journal:  Adv Immunol       Date:  2014       Impact factor: 3.543

6.  T-cell immunoglobulin and ITIM domain (TIGIT) receptor/poliovirus receptor (PVR) ligand engagement suppresses interferon-γ production of natural killer cells via β-arrestin 2-mediated negative signaling.

Authors:  Man Li; Pengyan Xia; Ying Du; Shengwu Liu; Guanling Huang; Jun Chen; Honglian Zhang; Ning Hou; Xuan Cheng; Luyu Zhou; Peifeng Li; Xiao Yang; Zusen Fan
Journal:  J Biol Chem       Date:  2014-05-09       Impact factor: 5.157

Review 7.  Targeting PVR (CD155) and its receptors in anti-tumor therapy.

Authors:  Paola Kučan Brlić; Tihana Lenac Roviš; Guy Cinamon; Pini Tsukerman; Ofer Mandelboim; Stipan Jonjić
Journal:  Cell Mol Immunol       Date:  2018-10-01       Impact factor: 11.530

Review 8.  Heart failure in cancer: role of checkpoint inhibitors.

Authors:  Murilo Delgobo; Stefan Frantz
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

Review 9.  Tim-3, Lag-3, and TIGIT.

Authors:  Nicole Joller; Vijay K Kuchroo
Journal:  Curr Top Microbiol Immunol       Date:  2017       Impact factor: 4.291

Review 10.  Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.

Authors:  Ana C Anderson; Nicole Joller; Vijay K Kuchroo
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.